1. Apoptosis
  2. MDM-2/p53
  3. Siremadlin succinate

Siremadlin succinate  (Synonyms: NVP-HDM201 succinate; HDM201 succinate)

目录号: HY-18658B
一键复制产品信息
产品使用指南 技术支持

Siremadlin (NVP-HDM201) succinate 是一种 MDM2 抑制剂和细胞周期调节剂。Siremadlin succinate 可阻断 MDM2 的 p53 结合口袋,抑制 MDM2 介导的 p53 泛素化与降解,从而在 p53 野生型细胞中激活 p53 通路。Siremadlin succinate 可用于皮肤黑色素瘤的研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Siremadlin succinate

Siremadlin succinate Chemical Structure

CAS No. : 1638193-48-2

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Siremadlin succinate 的其他形式现货产品:

Customer Review

Other Forms of Siremadlin succinate:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Siremadlin (NVP-HDM201) succinate is an MDM2 inhibitor and cell cycle regulator. Siremadlin succinate blocks the p53-binding pocket of MDM2, inhibits MDM2-mediated ubiquitination and degradation of p53, thereby activating the p53 pathway in p53 wild-type cells. Siremadlin succinate can be used in the research of cutaneous melanoma[1].

体外研究
(In Vitro)

Siremadlin (NVP-HDM201) succinate (72 h) 在 p53 野生型 (A375、WM35、C8161) 皮肤黑素瘤细胞系中,其生长抑制活性可被 2.5 μM GSK2830371 增强,但在 p53 突变型 (WM164、WM35-R、CHL-1) 细胞系中无此效应,具体表现为降低 Siremadlin succinate 的 GI50[1]
Siremadlin succinate 在 2.5 μM GSK2830371 的作用下,其细胞毒性在 p53 野生型 (A375、WM35、C8161) 皮肤黑色素瘤细胞系中被增强 (72 h),但在 p53 突变型 (WM164、WM35-R、CHL-1) 细胞系中无此效应,具体表现为降低了 Siremadlin (succinate) 的 LC50[1]
Siremadlin succinate (0.2 μM; 6 h, 24 h) 与 2.5 μM GSK2830371 联用可增强 p53 野生型 (A375、C8161) 皮肤黑色素瘤细胞系中 p53 的稳定性、磷酸化、乙酰化及转录活性[1]
Siremadlin succinate (0.2 μM; 24 h) 与 2.5 μM GSK2830371 联用时,可增强 p53 野生型 (A375、WM35、C8161) 皮肤黑色素瘤细胞系中 p53 依赖的细胞周期变化和细胞凋亡,但对 p53 突变型 (WM35-R) 皮肤黑色素瘤细胞系无此作用[1]
Siremadlin succinate 的活性在 2.5 μM GSK2830371 的作用下被增强,该效应在 p53 野生型 (A375, WM35) 皮肤黑色素瘤细胞系中严格依赖 p53[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: p53 wild-type (A375, WM35, C8161); p53 mutant (WM164, WM35-R, CHL-1) cutaneous melanoma cell lines
Concentration: 2.5 μM GSK2830371 (co-treatment)
Incubation Time: 72 h
Result: Significantly decreased the GI50 of HDM201 in p53 wild-type cutaneous melanoma cell lines compared to treatment with Siremadlin succinate alone.
Showed no potentiation in p53 mutant cell lines.\nSignificantly decreased the LC50 of siremadlin succinate in A375 and C8161 cells, and showed a similar trend in WM35 cells compared to treatment with Siremadlin (succinate) alone.
Showed no potentiation in p53 mutant cell lines.
分子量

673.50

Formula

C30H30Cl2N6O8

CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Siremadlin succinate
目录号:
HY-18658B
需求量: